Whoa! These 3 Stocks Are on the Ball: Pharmacyclics, Inc. (PCYC)

Page 2 of 2

For what once looked like a company on the brink of disaster, Vonage appears to be clawing its way back up to respectability.

Break on through to the other side!
Drug developer Pharmacyclics and its partner Johnson & Johnson (NYSE:JNJ) got a big boost from the FDA on Tuesday, as it granted their cancer drug candidate ibrutinib two breakthrough therapy designations, meaning the regulatory agency will accept preliminary clinical evidence showing that the drug offers significant improvements over currently available treatments.

As Foolish health-care analyst Max Macaluso notes, if Pharmacyclics can continue the string of positive developments it’s already achieved, it could earn nearly $1 billion in milestone payments from the pharmaceutical giant. It’s already received $300 million and stands to gain an additional $675 million if it ultimately meets its end points.

The designations don’t guarantee approval, and it still has some distance to run, but so far, Pharmacyclics appears headed in the right direction.

The article Whoa! These 3 Stocks Are on the Ball originally appeared on Fool.com and is written by Rich Duprey.

Fool contributor Rich Duprey has no position in any stocks mentioned. The Motley Fool recommends 3D Systems, Johnson & Johnson, Proto Labs, and Stratasys; owns shares of 3D Systems, Johnson & Johnson, and Stratasys; and has options on 3D Systems.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Page 2 of 2